RE:RE:RE:RE:Update the time line Or enrolment has been very slow, which could signal a longer time frame for the phase 1b trial as well. That is a very real possibility. The company could easily put that scenario to rest with a simple update but they've left it to investors to speculate on reasons for the delay
SPCEO1 wrote: Given that they already got to the 420mg level the likelihood of bad news on the MTD is minimal. It is more likely just good news or great news on the MTD. The news we would all like to see is a sign of preliminary efficacy and it is a 50/50 bet on that.
jeffm34 wrote: If the delay in the trial is due to good news, haven't seen any DLT's yet, I'm sure they would announce that. We can only assume now it's bad news. Would also explain the continued downward pressure on the stock price